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Posterior Drug Delivery via Periocular Route: Challenges and 
Opportunities  
 
Abstract  
Drug delivery to the posterior segment via periocular route is a promising route for delivery of 
a range of formulations. In this review, we have highlighted the challenges and the 
opportunities of the posterior segment drug delivery via the periocular route. Consequently, 
we have discussed different types of periocular routes, physiological barriers that limit effective 
drug delivery, practical challenges regarding patient compliance and acceptability and recent 
advances in developing innovative strategies to enhance periocular drug delivery. We 
conclude with a perspective of how we envisage the importance of understanding complex 
barrier functions so as to continue to develop innovative drug delivery systems.   
  
Keywords: periocular, posterior segment, drug delivery.  
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Introduction 
Drug delivery to the eye, even to the present day, is a difficult task and even more so when it 
comes to treating diseases and disorders that require drug delivery to the posterior segment 
[1]. The anatomical and physiological barriers that the ocular environment presents are unique 
and have led to various routes of administration, each with its own advantages and 
disadvantages [2]. Despite the issues in getting therapeutic drug levels in this part of the eye, 
the importance of successful delivery to the posterior segment cannot be underestimated, with 
the treatment of many proliferative, vascular and degenerative ocular diseases requiring it as 
a matter of course [3]. This review paper will highlight some of the major posterior segment 
diseases, routes of administration used to treat them – with a particular focus on the periocular 
route and the challenges it presents. Current research into this area is also discussed, to 
establish whether these challenges are being overcome, to and the future direction in 
periocular drug delivery. 
Diseases of the Posterior Segment 
Most prevalent eye diseases that cause visual impairment typically originates in the posterior 
segment of the eye (or back of the eye) and include age-related macular degeneration (AMD), 
diabetic retinopathy (DR), diabetic macular edema (DME), uveitis and retinitis. AMD is the 
leading cause of blindness among the aging population. A chronic disease of the central retina, 
specifically the macula, this disease is one of the leading causes of blindness and manifests 
itself in two broad types: neovascular (“wet”) AMD or geographic atrophy (“late dry”) AMD. In 
the “wet” form, choroidal neovascularization breaks through the retina leading to leaking fluids, 
lipids and blood resulting in fibrous scarring. The “late dry” form manifests as progressive 
atrophy of the RPE, choriocapillaris, and photoreceptors. Treatment methods for neovascular 
AMD consist of laser photocoagulation, photodynamic therapy and more recently the use of 
anti-VEGF (vascular endothelial growth factor) therapies [4]. The latter of these treatments is 
particularly significant here, as ranibizumab and bevacizumab, two of the drugs of this type, 
are currently delivered via intravitreal injection, showing the importance of delivery of the 
therapeutic agent into the ‘local’ area of the posterior segment for a therapeutic effect [5].  
Uveitis is simply inflammation of the uvea, a structure not just confined to the posterior 
segment of the eye, resulting in many sub-types of this [6], with posterior uveitis being the 
focus here. Posterior uveitis involves inflammation of the choroid, retina or both or the retinal 
vessels, with infection being the cause in over 40% of cases and includes toxoplasmosis, 
tuberculosis, candida, herpes simplex, zoster or cytomegalovirus [7]. Typically, this disease is 
treated with corticosteroids and immunosuppressant agents. While periocular delivery of 
steroids is an option; the oral route is preferred due to issues surrounding administration and 
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potential for ocular hypertension [8]. Some studies have also highlighted the use of intravitreal 
steroid injections as a treatment option, albeit with the recommendation being as a short-term 
treatment [9]. 
DR is commonly linked to patients that have diabetes mellitus [10], and it is the leading cause 
of blindness in adults of working age [11]. The loss of vision associated with this can be due 
to the non-clearance of vitreous humor or fibrosis, which then leads to retinal detachment 
through traction. Blood vessels can then leak causing permanent central vision loss-diabetic 
macular edema [12]. DME is the leading cause of visual impairment that occurs with DR. Lots 
of factors play a role in the development of the disease including; the degree of retinopathy, 
hypertension, glycemic control or lack thereof blood lipid and albumin levels and fluid retention 
[11,13]. Treatment options consist of focal or grid laser photocoagulation depending upon the 
nature of the DME, with the diffuse form being treated with the grid laser to cover the whole 
area [14]. Pars-plana vitrectomy has to be used in some cases to prevent visual loss, and 
intravitreal and sub-tenon delivery of corticosteroids have also been used [14,15]. Anti-VEGF 
treatments, again delivered by intravitreal injection, are also being investigated as treatment 
options [16]. Once again, while the treatments show promise, delivery of the drugs to the 
posterior segment in a safe and repeatable fashion is the issue. 
The diseases alluded to above and many others that affect the posterior segment of the eye 
have an influence on the patients’ vision and so have a significant impact on quality of life. As 
a result, treatment of these is of the utmost importance, requiring successful delivery of 
appropriate drugs, within the therapeutic window in a safe and repeatable fashion. While many 
drugs have shown promise in treating some of these, effective and safe delivery to the 
posterior segment is proving difficult.  
 
Drug Delivery to the Posterior Segment of the Eye 
Drug delivery to the eye can be achieved through different routes (Fig. 1), as discussed below. 
Topical Route 
Topical delivery is the most commonly used method of ocular drug delivery, more often for 
delivery to the anterior segment, to treat diseases such as glaucoma and conjunctivitis. Certain 
drugs are delivered via this route for the treatment of issues in the posterior segment. 
However, it is highly inefficient as less than 5% of the drug reaches the aqueous humor, with 
an even smaller proportion reaching the posterior segment due to a variety of barriers [17]. 
These include the dilution and flushing out of the drug by the tears, nasolacrimal drainage and 
tear turnover [18]. 
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Moreover, the cornea is a very effective barrier, possessing both lipophilic epithelial and 
endothelial layers and a hydrophilic stromal layer in between them, giving extremes of polarity 
as drugs would move through it, restricting their movement. There are also tight junctions 
present between the epithelial cells, making drug diffusion via the paracellular route difficult. 
A particular difficulty is seen with macromolecules, with only those of less than 50,000 Da 
being able to move through the stroma [19]. The endothelial layer within the cornea is also 
lipophilic, meaning that any drug would need an amphiphilic carrier and to possess both 
hydrophilic and lipophilic groups to move through the cornea effectively. Drugs are often 
rapidly cleared from the aqueous humor upon penetrating the cornea [20], but diffusion 
through the highly dense matrix of the vitreous humor is difficult [21]. Therefore, achieving 
therapeutic drug levels in the posterior segment through topical route such as eye drops, 
ointments, gels and drug-containing contact lenses is highly problematic.  
Systemic Route 
Systemic delivery, in the form of a patient taking an oral formulation, would be highly 
convenient and acceptable to patients it is not an automatic choice. Only a small proportion of 
systemically delivered drug gets to the posterior segment of the eye, largely due to the barrier 
properties of the blood-retinal barrier (BRB) [18] and low cardiac output to the retina [22], and 
thus large systemic doses are often required to achieve a therapeutically-effective drug 
concentration, which in turn can lead to significant side-effects [18]. Indeed, one study showed 
the intravitreal drug levels of poorly lipid soluble antibiotics, such as penicillins and 
cephalosporins are at maximum 10% of serum levels, resulting in frequent administration 
being necessary and systemic side-effects as a result [23]. Furthermore, with many drugs now 
being proteinaceous in nature, utilisation of the systemic route would lead to issues such as 
denaturation and low therapeutic effect as a result. 
Intravitreal Injections 
A drug delivery method that involves direct injection of a formulation into the vitreous humor 
via the pars-plana (Fig. 1) [24]. It achieves high concentrations of drug in the vitreous and at 
the neural retina with less systemic side effects than systemic delivery [25]. Solutions, 
suspensions, depots, liposomes and implants have all been delivered by this route, and many 
drugs used for the treatment of posterior segment diseases are delivered via this pathway 
[26]. However, the drugs of lower molecular weight are rapidly eliminated, thereby frequent 
administration becomes necessary, which in turn leads to an increased chance of problems 
associated with frequent injections, such as retinal detachment, retinal hemorrhage, and 
endophthalmitis [25,27]. There are also barriers to the retinal area, despite the proximity of the 
injection site to it. The inner limiting membrane (ILM) is immediately adjacent to both the retina 
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and the vitreous, and so is the primary barrier to diffusion of drugs into the retina [21]. 
Furthermore, the BRB, made up of both endothelial, epithelial cells and efflux transporters 
poses a barrier to inner-retinal cells [17,28]. Although the usefulness of this route cannot be 
debated due to the drug concentrations it is able to provide in the posterior segment, the 
invasiveness of the technique, especially if frequent administration or withdrawal of a non-
biodegradable implants, does prevent it from being the perfect answer. 
Periocular Routes of Drug Delivery 
Periocular route involves the delivery of drugs to the periocular area, the area that immediately 
surrounds the eye, and is thought to be a good compromise between lack of pain on delivery 
and efficiency for drug delivery to the posterior segment (Fig. 1) [1]. Furthermore, since this 
route targets the area surrounding the eye, there are less chances of some of the more 
worrying complications associated with intravitreal injections such as endophthalmitis, rise in 
intraocular pressure and retinal detachment [3], while simultaneously providing a close 
enough proximity to deliver detectable levels of the drug within 20-30 minutes after 
administration [1]. In comparison to intravitreal delivery, this method is found to be more 
efficient for delivery to the outer retina whereas intravitreal delivery is superior in the context 
of treating retinal ganglion cells and inner retinal interneuron disorders [29]. This type of 
delivery involves the insertion of drugs or drug delivery systems close to the sclera and 
consists of five sub-divisions; subconjunctival, retrobulbar, peribulbar, sub-tenon and posterior 
juxta-scleral route [24,30]. Following periocular delivery drugs move to the sclera via one of 
three pathways; the transscleral pathway, in the circulation via the choroid and through the 
anterior pathway (tears film, cornea, aqueous humor then vitreous humor) [31]. 
Subconjunctival route 
The subconjunctival route involves insertion of a formulation underneath the conjunctiva, 
which gives direct access to the sclera and therefore provides the transscleral pathway for 
drug diffusion. This route eliminates the need for the drug to diffuse through the conjunctival 
surface, which limits hydrophilic drug permeation [32] and the loss of drug due to the cleaning 
action of the mucus layer secreted by its goblet cells [1]. Typically, a needle of up 25 to 30-
gauge and 30 mm long can be used, with a maximum injection volume of 0.5 ml [3].  A variety 
of drugs have been successfully delivered via this route with high concentrations in the 
posterior segment achieved. For example, in a study dexamethasone showed higher levels in 
the subretinal fluid than those obtained with oral or peribulbar routes, suggesting that this 
method is capable of delivering a greater proportion of the drug load to the retina [33]. 
Retrobulbar route 
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This route of delivery involves an injection into the retrobulbar space, within the muscle cone 
[1] that is composed of the four rectus muscles and their intermuscular septa. This route is 
preferable when direct contact of the formulation with the macula is required [1], usually using 
a blunt 25 or 27-gauge needle due to there being a reduced chance of eye injury [3]. The 
retrobulbar space can accommodate up to 2-3 ml of a solution [1]. 
Peribulbar route 
An injection that is external to the four-rectus muscles and their intermuscular septa, this route 
is an alternative to the retrobulbar route, with a lower chance of ocular injury [3]. Injections can 
be either inferior or superior in nature [3], with an injection into the inferior-lateral quadrant 
using a 26-gauge 0.25 inch needle [34] and temporal administration (a type of superior 
injection) using a 25-gauge 1.25 inch needle. Volumes of 8-10 ml can be delivered using this 
route. Despite being a safer route in comparison to the retrobulbar route, it is also less effective 
when being used for anesthesia of the globe [3]. 
Sub-tenon route 
Anatomically speaking the tenon’s capsule is made up of connective tissue located between 
the conjunctiva and episcleral plexus and the space between the capsule and the sclera is the 
sub-tenon’s space containing anterior and posterior segments [35]. It surrounds the eye and 
extraocular muscles in orbit, originating in the limbus and extending back to the optic nerve 
[36]. For anesthesia, a 1-inch blunt-tipped cannula is used, with a volume of administration of 
up to 4 ml [3,36]. Posterior sub-tenon injections use a 26-gauge, 5/8-inch needle to administer 
the drug into the posterior sub-tenon space [3]. This route has its advantages because the 
avascular nature of the tenon’s capsule increases drug contact time with the sclera and when 
the blunt cannula can be used for anesthetic delivery [35], sharp-needle issues are 
removed[3]. The route does, however, suffer from poor penetration of drug through the sclera 
and choroid and choroidal clearance [35]. 
Posterior Juxtascleral route 
This route is a more recent method that was used to deliver anecortave acetate for the 
treatment of subfoveal neovascularization in AMD. It utilizes a blunt-tipped curved (56º) 
cannula to place the drug on the surface of the sclera without penetration of the eyeball. This 
method was used to deliver the drug close to the macula to maximize treatment effectiveness 
[30]. Studies have shown that this method of delivery to be a safe and effective for delivery of 
drug molecules to the choroid and retina in the macular region for up to six months [37]. Table 
1 summarizes overall benefits and challenges of different routes of drug delivery to the 
posterior segment of the eye.  
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Challenges of Periocular Drug Delivery 
Despite the advantages that periocular delivery has, it is not without challenges when it comes 
to delivery of therapeutically effective concentrations of drug to the target site in the posterior 
segment. There are many physiological barriers, safety concerns and issues that would hinder 
patient compliance.   
One of the major issues faced using periocular delivery are the physiological barriers that need 
to be crossed to get therapeutically effective drug concentrations at the target site within the 
posterior segment. The direct penetration pathway is via the sclera, choroid, RPE, retina, outer 
limiting membrane, ILM and then into the vitreous, in that order [3]. Furthermore, drugs can 
also move via the anterior chamber to the vitreous humor and via the systemic circulation, 
where it moves out of the periocular space in conjunctival, episcleral or choroidal vessels into 
the systemic circulation and then back into the ocular circulation. The drug can also permeate 
through the anterior chamber where it diffuses into the aqueous humor either directly or via 
the sclera and ciliary body or via the tear fluid and cornea after it has been refluxed through 
the conjunctiva. Within these different pathways, there are three main types of barriers namely 
static, dynamic and metabolic [38].   
Static Barriers 
The Sclera 
The scleral barrier is continuous with the cornea, with its origin in the limbus from which it 
extends throughout the globe [32]. Anatomically the sclera is similar to the stromal layer of the 
cornea [39], consisting of an extracellular matrix with embedded collagen fibers and 
proteoglycans [40]. As a result, the sclera’s permeability is also similar to that of the corneal 
stroma [39,40], with greater permeability than that of the overall cornea, having a larger 
surface area (16.3 cm² compared to around 1 cm² [40]) and lower protease activity [24]. 
Permeability is inversely proportional to molecular radius and this property, rather than 
lipophilicity is what has the main effect on scleral permeability [39]. However, increased 
lipophilicity causes a decrease in permeability [41]. It has also been found that positively 
charged molecules permeate the sclera less effectively, due to the negatively charged 
proteoglycans within the extracellular matrix [42]. Although certainly not entirely permeable, 
the sclera is not one of the main rate-limiting barriers to be overcome for drugs to reach the 
posterior segment. 
The Choroid and Bruch’s Membrane 
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The next rate-limiting barrier is the choroid [3]. Choroid majorly consists of blood vessels, 
providing a blood supply for the outer retina [43]. The choroid and Bruch’s membrane form a 
static layer to drug permeation, with permeability decreasing with increasing molecular weight 
and lipophilicity and similar to the sclera, permeation is reduced with positively charged 
molecules [44]. The barrier property changes with age, as the choroid, gets thinner and the 
Bruch’s membrane thickens, which alters drug permeation over time [45]. For example, the 
permeability of taurine through the Bruch’s membrane-choroid complex reduces with 
increased thickness of the Bruch’s membrane, suggesting it may be a significant barrier to the 
permeability of small solutes [46].  
The Retinal Pigmented Epithelium (RPE) 
The RPE is another static barrier and is also known as the outer blood-retinal barrier (oBRB), 
which in combination with the inner blood-retinal barrier (iBRB) make up the blood-retinal 
barrier [38], which is the barrier responsible for restricting movement between the blood and 
the retina. The iBRB relies on Müller cells and retinal capillary vessels to maintain its proper 
function, which is to control the uptake of nutrients and the release of metabolites. If drugs 
move into the circulation they can then bypass the iBRB via the choroid, so the oBRB is 
responsible for restricting movement of drugs from the choroid into the retina, and is, therefore, 
a highly significant static barrier [38]. Formed from specialized hexagonally shaped cells, the 
RPE forms a cellular barrier, and its efficiency is further augmented due to the presence of 
tight junctions between the cells, restricting movement via the paracellular route [38,42]. 
Studies have shown that permeability decreases with an increase in molecular radius and 
increase with increasing lipophilicity [42,44] and also that taurine permeability across BC-RPE 
barriers was lower than across BC alone, which would suggest that RPE is the layer that limits 
its penetration [47].  
Dynamic Barriers 
Dynamic barriers that can reduce the drug levels in the posterior segment of the eye, including 
blood flow, lymphatic clearance, transport proteins present on the RPE, bulk fluid flow, drug 
efflux pumps and organic ion transporters [38,42]. 
Conjunctival/Episcleral Clearance 
Many studies have shown that the drug present in conjunctival and episcleral tissues is cleared 
due to blood and lymphatic flow. For example, when a ‘conjunctival window’ was made by an 
incision to inhibit blood and lymphatic clearance, higher triamcinolone acetonide levels were 
attained in the vitreous humor, which clearly shows this is a noteworthy barrier and in this case 
of greater significance than clearance due to choroidal blood flow [48].         
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Choroidal Blood Flow 
Choroidal flow is considered in some quarters to be one of the main barriers to drug 
permeability into the posterior segment [3], but as referred to earlier, this is up for debate. The 
issue is that the extent to which choroidal blood flow is a barrier cannot be determined by 
simply by measuring systemic drug levels because there are more paths that the drug can 
take than just choroidal blood flow including the clearance via conjunctival vessels mentioned 
earlier. The study involving the sub-tenon delivery of triamcinolone acetonide utilized 
cryotherapy to eliminate the effect of choroidal blood flow, and those rabbits that received the 
cryotherapy didn’t have higher vitreous drug levels suggesting that choroidal blood flow 
doesn’t significantly contribute to a reduction in drug levels in the posterior segment via 
transscleral delivery [48]. Conversely, another study involving subconjunctival delivery found 
that clearance by the blood was of greater significance than that of lymphatic clearance [49], 
although the type of periocular delivery and drug used were different. More studies must be 
done, however, as it is clear that this finding is not universally accepted [3,32]. Convective flow 
within the eye is also thought to play a role in drug elimination, moving most of the drug into 
the choroidal and conjunctival vessels [42]. 
Osmotic and Hydrostatic Pressure 
Osmotic and hydrostatic pressure differences between certain areas in the eye also contribute 
to outward bulk flow and drug elimination. There is an osmotic pressure difference between 
the choroid and the vitreous which leads to bulk flow in the direction of the choroid [42], while 
there is also a hydrostatic pressure difference between suprachoroid and episcleral tissue also 
lead to outward bulk flow [50].  
RPE Transporters  
Transporters are present on the RPE may have a significant role in drug transport, however 
much more research into this area is required [51]. There are various types of ion and amino 
acid transporters and significantly drug efflux pumps. Transporters for amino acids such as 
glutamate, taurine, gamma-aminobutyric acid (GABA) and leucine have been found on the 
RPE, and it is thought that these may have some role in drug transport, as well as 
physiologically. There are also oligopeptide transporters that have been shown to have a role 
in cephalosporin transport across the retina [52] and organic cation transporters, of interest 
due to many current drugs being of this nature including sympathomimetics, antihistamines 
and vitamins [51]. Efflux proteins are thought to be of high importance when it comes to drug 
permeation through the RPE, although they haven’t been widely studied [51]. Efflux pumps of 
the ATP-binding cassette family include P-glycoprotein (P-gp) and multidrug resistant proteins 
(MRP) and these pump drugs from cells into the extracellular space [53]. Generally speaking, 
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P-gp pumps eliminate large neutral or cationic compounds, and the MRP pumps eliminate 
large neutral or anionic compounds [54]. It has been found that both of these pumps move 
compounds, including drugs, towards blood in the BRB [55]. They remove compounds via the 
choroidal circulation and ultimately the systemic circulation. Overall the RPE is thought to be 
equal in importance to the sclera in terms of the permeation of small lipophilic molecules and 
more importantly large or hydrophilic molecules [56]. 
Metabolic Barriers 
These barriers involve the cytochrome P450 system, a family of haem-containing isozymes 
that are involved in around 80% of oxidative drug metabolism and around 50% of drug 
elimination [57], and lysosomal enzymes [38,42]. Both types of the enzymes can detoxify or 
even degrade drug compounds, ultimately reducing drug concentration in the posterior 
segment. High levels of cytochrome P450 enzymes have been found in both mouse and 
bovine RPE, and this combined with the high level of interaction this enzyme system has with 
modern drugs, means this barrier is certainly worthy of serious consideration. Lysosomal 
enzymes are found in lysosomes within cells, and some drugs can enter these structures via 
passive diffusion [58]. Exposure to the lysosomal enzymes could, therefore, lead to 
degradation since these enzymes are known to have a broad spectrum of activity [59]. 
Hydrolytic enzymes are also present in the retina as well as aldehyde oxidase, ketone 
reductase and conjugating enzyme systems which have been characterized in the ocular 
tissues of different animals as detailed by Attar et al. [54]. This evidence would suggest that 
there is a lot more research to be done in understanding the presence of different ocular 
enzymes in humans and its effect on the ocular bioavailability of drugs.   
Clearly, when it comes to the dynamic and metabolic barriers to the ocular delivery, there is a 
lot less information and evidence of understanding of these in the literature. To get a more 
detailed picture of the barriers to periocular delivery more research needs to be done into 
these areas, something that was also concluded by Kim et al. in their review of the barriers to 
transscleral drug delivery [42]. 
 
Practical Challenges 
Even though the periocular route is less invasive and safer than the intravitreal route, it is not 
entirely without complications. Sub-tenon injections are associated with chemosis and 
subconjunctival hemorrhage with incidence rates of 39.4% and 32-56% respectively, and this 
is despite the fact that this is one of the ‘safer’ periocular delivery methods. Retrobulbar 
injections are associated with retrobulbar hemorrhage, globe perforation and respiratory arrest 
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(when used for anesthetic delivery due to brainstem anesthesia), with incidences of 1.7%, 
0.75%, and 3% respectively. The peribulbar route is associated with a significantly lower rate 
of globe perforations (0.0008% compared to 0.75%) than retrobulbar and no incidence of the 
other two issues [3,32].  
The very nature of periocular delivery means that specialist ophthalmologists and centers are 
required to administer treatment via this route, especially with technology such as real-time 
tomography reflection of sonographic images are being used in efforts to make peribulbar and 
retrobulbar delivery safer. The requirement of specialist equipment means that compliance is 
likely to be affected, especially if repeated treatments are required. Logically, this can be 
overcome by using implantable devices to deliver the drug over a prolonged period, reducing 
the number of separate treatment procedures, but these in themselves present significant 
challenges, such as burst release, dose dumping, and low bioavailability [60]. Biodegradable 
implants are useful, as they don’t need to be retrieved after implantation, but are more likely 
to have issues such as burst release and poor linearity of release [61]. Non-biodegradable 
implants do give a more predictable and controlled release over time but are more invasive 
due to their removal being necessary. Moreover, non-biodegradable systems can potentially 
trigger immune responses, while larger implants produce foreign bodies like reaction – 
resulting in the surface attraction of fibroblasts, foreign body giant cells, and macrophages, 
leading to the formation of a fibrous capsule which in turn can prolong its degradation and 
elimination [62]. This reaction, in turn, restricts drug bioavailability and the longevity of the 
treatment period for the implant. 
 
Strategies to Improve Periocular Delivery 
A variety of different formulations and techniques are currently researched for periocular 
delivery, including implants, gels, microparticles (1-1000 µm) and nanoparticles (1-1000 nm) 
alongside many other colloidal systems to provide formulations that give controlled and 
sustained release of their active pharmaceutical ingredient (API). Moreover, non-invasive or 
minimally invasive techniques such as iontophoresis and microneedles have also been 
researched for transscleral delivery to improve the penetration of drug or sustained release 
formulations. Table 2 shows some examples of small and large drug molecules and routes for 
administration for treating posterior segment eye diseases. These drug molecules vary widely 
in their molecular size that causes significant challenge in effective permeation across trans-
scleral/periocular barriers. Therefore, a range of formulation approaches have been 
investigated to improve periocular delivery, as described below.    
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Micro-/Nano-particles have seen varying levels of success. For example, subconjunctival 
administration of budesonide solution and budesonide-loaded microparticles (3.6 µm) and 
nanoparticles (345 nm) achieved higher retinal levels, with the microparticles showing 
superiority to other formulations in terms of sustained delivery. It is likely due to the greater 
retention potential of the microparticles in the periocular space compared to the nanoparticles. 
There was, however, an initial burst release of 25 % from the nanoparticles, something that is 
often seen with this type of formulation. The microparticles exhibited no discernible burst 
release, probably due to the reduced surface drug due to a surface area of microparticles, but 
the sheer size of the particles means that local tissue irritation is more likely [63].   
A study by Amrite et al. also showed that an increase in particle size leads to higher residence 
times at the injection site, which ultimately leads to greater drug levels in the target tissue for 
longer. Similarly, higher particle size (approximately 200 nm) is also shown to reduce removal 
clearance by the lymphatic and choroidal circulation [64,65]. Furthermore, the periocular route 
has been used to deliver celecoxib-containing microparticles to the posterior segment, 
following subconjunctival injection and were capable of providing drug release over a 14-day 
period and reducing diabetes-induced biochemical markers [66]. More recent research in a 
collaborative effort between Santen Pharmaceuticals and Oakwood Laboratories is showing 
promise, with the development of a biodegradable PLGA microsphere using Oakwood 
Laboratory’s Chroniject system that is capable of releasing betamethasone periods from 10 
days to 1 year [67,68].   
Liposomes are vesicular systems, with very similar structures to that of a phospholipid bilayer. 
Typically, these systems range from 10 nm to 10 µm in size, with the small unilamellar vesicles 
being 10-100 nm and the large unilamellar vesicles being 0.1-10 µm. It is also possible to have 
multilamellar systems consisting of more than one bilayer [1,17]. Due to the presence of both 
hydrophilic and hydrophobic compartments, these formulations can incorporate drugs of both 
types into their structure and have been used for delivery of a variety of antibiotics and antiviral 
agents [69]. Liposomes have been used to a limited degree in periocular drug delivery, with 
one example being in the delivery of a periocular vaccine against HSV infection in rabbits. 
This vaccine was actually shown to be more effective in this capacity than systemic 
vaccination [70].  
Hydrogels are another formulation strategy that has been researched to improve periocular 
delivery. In particular, for posterior segment delivery, hydrogels have been placed 
subconjunctivally. For example, a hydrogel formulation has been used to deliver insulin for the 
treatment of DR. The ratio of N-Isopropylacrylamide (NIPAAm) to dexamethasone-lactate-
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Hydroxyethylmethacrylate (HEMA) was altered with the best formulation achieving insulin 
release for 18 days, with the activity of the insulin being similar to that of control insulin [71]. 
Implants have also been investigated and while zero-order in vitro and in vivo release has 
been demonstrated, the release time was only for four weeks [72] – far shorter than what 
would probably be required for patient compliance and acceptability in posterior segment 
treatments. A bioerodible dexamethasone implant has also been developed for the treatment 
of uveitis and postoperative cataract inflammation, that was capable of near zero-order release 
for six weeks with histological studies showing no signs of inflammation [73]. As mentioned 
above these come in biodegradable and non-biodegradable forms, with different advantages 
and disadvantages, but with polymer research always evolving an implant that meets the 
needs from a pharmacological and practical point of view is not too far away. Essentially, non-
biodegradable implants can provide the controlled release and release duration required, but 
their size, the need for surgical attachment and the fact that they need to be removed again 
are major drawbacks.  
Huang et al. also very recently used a capsular drug delivery system inserted into the sub-
Tenon’s sac of New Zealand rabbits, which showed sustained release of dexamethasone 
sodium phosphate over a 56-day period [74]. However, this hasn’t yet been carried out in vivo 
in humans, and the release period is probably too short for patient compliance if they have 
chronic conditions. Nevertheless, it shows research into sustained release systems delivered 
via the periocular route is heading in the right direction. 
Iontophoresis, a technique that utilizes the application of a small electrical current to the 
outside of the eye, is designed to enhance drug penetration into the posterior segment without 
the need for a surgical procedure. This technique has been shown to improve the transscleral 
penetration of a variety of drugs, including steroids, antibiotics, and macromolecules and can 
deliver high concentrations of drug to the choroid and retina. Many devices such as Eyegate 
[75], Eyegate II [76] and Ocuphor [77] have been developed with ease of use is a primary 
concern. Although promising, the technique does have some problems, such as epithelial 
edema, decrease in endothelial cells and even burns depending on the levels of current used 
and the exposure times [77].   
Microneedles initially developed for transdermal delivery, are a novel approach for minimally 
invasive delivery of drugs across the sclera using needles in the micron’s range (e.g. 100 -
1000 μm). As discussed in the review paper by Thakur et al. they are a relatively new 
periocular approach that allows for local and minimally invasive drug delivery thereby holds 
the potential for improving patient compliance. They also reduce the clinical and technical 
complications associated with the use of hypodermic needles, whilst still potentially allowing 
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for penetration of ocular barriers for the localized delivery of both drug and formulations. When 
they have been used in studies to deliver small amounts of drug formulations to areas such 
as the sclera and suprachoroidal space, no damage to the sensitive tissue has been noticed 
[78]. These systems can be used to deliver controlled release formulations such as 
microparticles and nanoparticles. One example of such research is that of Jiang et al. which 
involved the use of hollow microneedles to deliver, 10-35 µl, of model drug solution, 
nanoparticles, and microparticles. For the former two substances researched, the 
microneedles were simply allowed direct deposition of the payload, whereas in the latter 
enzyme (hyaluronidase) was used to accommodate microparticles due to its large size [79]. 
Patel et al. used hollow microneedles for the delivery of bolus drug, microparticles, and 
nanoparticles into the suprachoroidal space via the sclera, consistently achieving delivery 
volumes of 35 µl [80]. Microneedles have also been in our group used to deliver intrascleral 
thermoresponsive implants that were capable of localizing delivery of thermo-responsive 
hydrogel implants (Fig. 2), which was then able to provide sustained release [81]. Our group 
also investigated dissolving implant forming microneedles to increase penetration across the 
scleral tissue, and whilst their effectiveness for small molecules was limited, they did show 
significant penetration enhancement with macromolecules (Fig. 3), so could have a significant 
role in the future of periocular delivery [82]. This technique is limited though due to the very 
limited nature of research that has been done, so there is a need to demonstrate safety and 
efficacy. The injection volumes achieved are also very small, so the duration of action of any 
would-be intrascleral depot would be limited as a result. 
Unlike delivery of small molecules, periocular delivery of high molecular weight proteins (e.g. 
anti-VEGFs such as bevacizumab, ranibizumab, and aflibercept) needs special attention. This 
is due to the challenges associated with physicochemical properties of the proteins, stability, 
permeation and formulation issues. Therefore, proteins are directly injected into the eye using 
intravitreal injections [83]. For example, the static and the dynamic barriers, as discussed 
above, also restrict adequate permeation of protein drugs in the target ocular tissues. 
Furthermore, due to the large size, charge, in vivo interaction with other chemical moieties, 
enzymatic degradation, periocular clearance and stability issues - proteins delivery results in 
low efficiency and low bioavailability, posing additional challenges for the successful delivery 
of protein drugs to the target sites [84]. The unique physicochemical properties of the proteins 
posses’ significant challenges in developing suitable formulations. However, recently some 
formulation approaches have been developed to overcome these concerns, including 
nanoparticles, microparticles, in situ-forming gels and preformed implants, as discussed 
above. Importantly, the rationale behind these innovative formulations for protein-based 
therapeutics are to (i) improve in vivo stability and protecting from denaturation; (ii) increasing 
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the permeability of the protein across biological membranes to achieve higher bioavailability; 
and (iii) providing sustained protein release at the target site.  
Injectable protein-loaded nano/micro-particles can provide sustained release and facilitate 
protein permeation across ocular barriers [85]. One advantage of nanoparticles is that they 
can enter cells, which provides the possibility of delivering protein intracellularly [86]. 
Sustained drug delivery to the target ocular tissue, especially the posterior segment, through 
periocular administration would require prolonged retention time of the delivery systems at the 
periocular site. The size of nanoparticles greatly affects their retention time after periocular 
administration. For example, particles ranging from 200 to 2000 nm were almost completely 
remained after subconjunctival administration for at least two months, while 20 nm particles 
were cleared rapidly from the site of administration [65,87]. For example, the release of 
bevacizumab (Avastin®) loaded polylactic-co-glycolic acid (PLGA) nano- and microparticles 
can be sustained for over 91 days [88]. However, the exposure of bevacizumab to organic 
solvents during the particle preparation can compromise its activity, which was overcome by 
using albumin as a stabilizer in the particle formulation process [89].  
Hydrogels usually possess high compatibility and have been used as ocular drug delivery 
systems to prolong the retention time and bioavailability of the incorporated drugs [90]. Several 
polymeric gelling systems, such as chitosan, poloxamers, hydroxypropyl cellulose, 
hydroxypropyl methylcellulose, poly (N-isopropylacrylamide) and copolymers composed of 
polycaprolactone (PCL), polyethylene glycol (PEG) and PLGA, have been used as ocular 
delivery systems. Hydrogel-based ocular drug delivery systems can be divided into in situ-
forming gels and preformed gels. In situ-forming gels involve polymeric solutions which 
undergo a sol-gel transition to form a gel in response to a stimulus, including changes in 
temperature, pH, and ionic composition, as well as UV exposure [91]. Thermo-responsive 
gelling systems are one of the most studied in situ gelling systems since these systems 
undergo in situ gelation once injected into the body, providing a great opportunity for the 
development of injectable ocular drug delivery system [90]. In situ gelling systems are 
generally used to prolong the residence time of protein drugs at the administration site and 
enhance bioavailability. In an in vivo study, ovalbumin concentrations can be maintained at 
measurable levels in the sclera, choroid, and retina of rats for up to 14 days after 
subconjunctival injection of a PLGA-PEG-based thermo-gelling delivery system [92].  
Preformed gels are usually administered by subconjunctival implantation to delivery 
therapeutic agents to the posterior segment of the eye. The main advantage of preformed gels 
is that the sol-gel transition happens in vitro. This will minimize in vivo tissue irritation and 
systematic toxicity caused by the burst release during the sol-gel transition, which is the major 
drawback of in situ-forming gels [93]. Misra et al, developed insulin-loaded hydrogels 
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synthesized by UV photopolymerization of N-isopropylacrylamide (NIPAAm) monomer and a 
dextran macromere [71]. The hydrogels can release biologically active insulin in vitro for at 
least one week. The hydrogels showed no toxicity to retinal neuron cells and high compatibility 
after subconjunctival implantation. In an in vivo study, these insulin-loaded hydrogels were 
administered via subconjunctival implantation in diabetic rats. The results indicate that insulin 
released from the implanted hydrogels can penetrate into the rat retina in a sustained manner, 
and rescue retinal cells from apoptosis in diabetic rats [94]. 
Future Perspective 
Drug delivery to the posterior segment of the eye is clearly very important for the treatment of 
many of the more serious ocular diseases and with an ever-growing and aging population, its 
importance is only going to increase. The periocular route offers clear advantages over the 
topical and systemic routes of administration for delivery to the posterior segment and has 
advantages over the intravitreal route too, particularly in the context of invasiveness and 
patient safety. 
Strides are always being made in ocular drug delivery, and in particular to periocular delivery 
the future probably goes hand-in-hand with the ever-evolving field of polymer science, which 
could potentially yield a biodegradable and indeed biocompatible system that can deliver its 
yield over a period of months to years, without the all too familiar issues of dose dumping and 
burst release. Although a system such as this may not be imminently available for patients, it 
is certainly not an unrealistic aim for the future, and if it were possible for it to be self-
administered, as stated by Thrimawithana et al. –  an ‘ultimate solution’ [24]. There is 
significant evidence of research into protein delivery via the periocular route, with 
nano/microparticles and hydrogels being popular. Other formulations could be utilized for this 
purpose and will probably be seen more regularly in the future, as well as formulations capable 
of delivering their protein over longer time periods, which will be key in the treatment of chronic 
posterior ocular disease. Furthermore, techniques such as iontophoresis and microneedle 
delivery are clearly promising and improve drug and formulation penetration through the 
numerous physiological barriers within this delivery route, so a combination of this with the 
above could be very beneficial for the treatment of disease in the posterior ocular segment 
and patient acceptability. Ultimately research is going to be focused on improving the 
bioavailability of therapeutic agents in the posterior segment via periocular delivery, while also 
striving for patient safety, a reduction in the complications and minimal adverse effects. That 
being said, if the possibility of a device that allows for safe and effective, self-administered 
periocular delivery becomes a reality-combining effective periocular delivery and patient 
compliance it would revolutionize the treatment of ocular diseases. However, these studies 
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will have to take into account the different barriers to periocular delivery, particularly the 
dynamic and metabolic barriers, due to the lack of research in these areas. Moreover, 
physiological barriers are often very different in the disease state, something which will need 
to be considered to a greater detail for development of successful treatment strategies via 
periocular delivery.  
 
Executive Summary  
Posterior Segment Drug Delivery  
 Posterior segment of the eye diseases are on the rise with increasing aging population. 
 Drug delivery to the posterior segment can be achieved by a number of routes such 
as topical, systemic, periocular, and intravitreal routes  
Periocular Drug Delivery  
 Periocular route offers clear advantages over the topical and systemic routes of 
administration and has advantages over the intravitreal route too, particularly in the 
context of invasiveness and patient compliance. 
 Following periocular administration, static, dynamic, and metabolic barriers must be 
overcome to get therapeutically effective drug concentrations at the target site within 
the posterior segment. 
 Periocular injections are not without side effects such as chemosis, hemorrhage, globe 
perforation and respiratory arrest. And, need for sophisticated facilities such as real-
time tomography reflection of sonographic images being used in efforts to make 
peribulbar and retrobulbar delivery safer. 
Ongoing developments 
 A variety of different formulations and techniques have and are being researched for 
periocular delivery, including hydrogels, implants, devices, and micro/nanoparticles so 
as to provide sustained release of the API. 
 Modified release systems provide great opportunity to reduce the frequency of 
periocular injections and thereby improve patient compliance. Non-invasive and 
minimally invasive techniques such as iontophoresis and microneedles provide new 
opportunities to further reduce the invasiveness of periocular drug delivery. However, 
more research is needed in this area.  
 Periocular ocular route combined with innovative sustained release systems provides 
safe and effective posterior drug delivery than its counterparts. However, a thorough 
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understanding of barriers, both in healthy and disease state, is much needed for 
successful treatments via periocular delivery.  
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Figure captions 
Figure 1. Different routes of periocular delivery.  
Figure 2. Optical coherence tomography images showing 30 G hollow microneedle injection 
of thermoresponsive hydrogel (coloured in red) injected into sclera to a depth of 400 μm at (a) 
0, (b) 1 and (c) 2 h. The arrow indicates empty space in sclera created following hollow 
microneedle application and its subsequent closure over time. Adapted with permission 
[81], 2014, Wiley. 
Figure 3. A schematic diagram of periocular administration of dissolving microneedles (MNs) 
– the left hand side represents the collection and processing of confocal images of scleral 
tissues following application of MN arrays, where (a) topical image of tissue after 5 min 
following insertion of MN array, (b) cross section image of tissue after 5 min following MN array 
insertion, (c) topical image at a depth of 80 µm from surface of the tissue after 1 hr following 
MN insertion, and (d) cross section image of tissue 1 hr after applying an aqueous drug 
solution. Adapted with permission [82], 2016, Springer 
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Table 1. Benefits and challenges of different routes of drug delivery to the posterior segment 
of the eye. Adapted with permission [39], 1998, Wiley. 
 
Route of Administration Benefits Challenges 
Topical High patient compliance, self-
administrable and non-invasive 
Higher tear dilution and turnover rate; 
cornea acts as a barrier, efflux pumps, 
and low bioavailability (< 5%) 
Oral (systemic) Patient compliant and non-invasive 
route of administration 
Blood-aqueous barrier, BRB, high 
doses causing toxicity and low 
bioavailability (< 2%) 
Intravitreal Direct delivery to the vitreous and 
retina; overcomes BRB function  
Highly invasive, retinal detachment, 
hemorrhage, cataract, endophthalmitis, 
and low patient compliance 
Subconjunctival Delivery to both anterior and 
posterior segment and easy 
administration of depot formulations 
Conjunctival and choroidal circulation 
act as barriers 
Subtenon High vitreal drug levels, relatively 
noninvasive, fewer complications 
unlike intravitreal delivery 
Retinal pigmented epithelium (RPE), 
chemosis, and subconjunctival 
hemorrhage 
Retrobulbar Administer high local doses of 
anesthetics, more effective than 
peribulbar, minimal influence on 
intraocular pressure 
Retrobulbar hemorrhage, globe 
perforation, and respiratory arrest 
Posterior juxtascleral Safe for delivery of depot formulation, 
sustain drug levels up to 6 months to 
the macula, avoids risk of 
endophthalmitis and intraocular 
damage 
Requires surgery and RPE acts as 
barrier 
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Table 2. Examples of small and large drug molecules used in the treatment of the posterior segment 
eye diseases. 
Drug molecule Indication Delivery route 
Dexamethasone DME and uveitis Intravitreal  
Fluocinolone 
acetonide 
Chronic non-infectious 
uveitis, DME 
Intravitreal  
Celecoxib Diabetes Periocular injection  
Insulin lispro Diabetic retinopathy Subconjunctival hydrogel 
Ganciclovir Antiviral Intravitreal 
Budesonide Anti-VEGF treatment Subconjunctival 
micro/nanoparticles 
Triamcinolone 
acetonide 
Wet-AMD Transscleral (sub-tenon 
injection) or intravitreal 
injection 
Bevacizumab 
(Avastin®) 
Wet-AMD and DME Intravitreal  
Ranibizumab 
(Lucentis®) 
Wet-AMD, DME and 
retinal vein occlusion 
 
Intravitreal  
Afibercept 
(Eylea®) 
Wet-AMD, DME and 
retinal vein occlusion 
 
Intravitreal  
 
 
   29
   30
   31
   32
 
